Literature DB >> 27673755

Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of 18F-FP-DTBZ in baboons.

Mika Naganawa1, Shu-Fei Lin1, Keunpoong Lim1, David Labaree1, Jim Ropchan1, Paul Harris2, Yiyun Huang1, Masanori Ichise2, Richard E Carson1, Gary W Cline1.   

Abstract

INTRODUCTION: 18F-Fluoropropyl-(+)-dihydrotetrabenazine (18F-FP-(+)-DTBZ) is a vesicular monoamine transporter type 2 (VMAT2) radiotracer for positron emission tomography (PET) imaging to quantify human β-cell mass. Renal cortex and spleen have been suggested as reference regions, however, little is known about 18F-FP-(+)-DTBZ binding in these regions including the fraction of radiometabolite. We compared the kinetics of 18F-FP-(+)-DTBZ and its inactive enantiomer 18F-FP-(-)-DTBZ in baboons, estimated the non-displaceable binding (VND) of the tracers, and used ex vivo studies to measure radiometabolite fractions.
METHODS: PET scans were conducted for up to 4h with (+) and (-) enantiomers. Displacement experiments using unlabeled (+) and (-) enantiomers of FP-DTBZ and fluvoxamine (to evaluate sigma-1 receptor binding) were performed. SUV curves were used to calculate displacement values in the pancreas, renal cortex, and spleen. Distribution volumes (VT) were computed, and three approaches for calculation of VND were compared: (1) 18F-FP-(+)-DTBZ reference VT, (2) 18F-FP-(-)-DTBZ pancreatic VT, and (3) a scaled 18F-FP-(+)-DTBZ reference VT values. Ex vivo study was conducted to measure radiometabolite fraction in homogenized tissue samples from baboons at 90min post-injection.
RESULTS: Spleen uptake was lowest for both tracers. Highest uptake was in the pancreas with 18F-FP-(+)-DTBZ and renal cortex with 18F-FP-(-)-DTBZ. Substantial displacement effect was observed only with unlabeled FP-(+)-DTBZ in the 18F-FP-(+)-DTBZ studies. Radiometabolite fraction was higher in the renal cortex than the spleen. Approaches (1) and (3) with spleen to estimate VND provided lowest inter-subject variability of BPND.
CONCLUSIONS: VT differences among organs and between enantiomers indicated that scaling of reference region values is needed for quantification of VMAT2 binding in the pancreas with 18F-FP-(+)-DTBZ. Since the kidney PET signal has greater partial volume averaging and more radiometabolites, the spleen was considered a more practical candidate for use as a scaled-reference region in the quantification of 18F-FP-(+)-DTBZ in the pancreas.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (18)F-FP-(+)-DTBZ; (18)F-FP-(−)-DTBZ; PET; Pancreas non-displaceable binding; Vesicular monoamine transporter type 2; β-cell mass

Mesh:

Substances:

Year:  2016        PMID: 27673755      PMCID: PMC5248981          DOI: 10.1016/j.nucmedbio.2016.08.018

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  19 in total

1.  Strategies to improve neuroreceptor parameter estimation by linear regression analysis.

Authors:  Masanori Ichise; Hiroshi Toyama; Robert B Innis; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2002-10       Impact factor: 6.200

2.  Identification of tissue-restricted transcripts in human islets.

Authors:  Antonella Maffei; Zhuoru Liu; Piotr Witkowski; Federica Moschella; Giovanna Del Pozzo; Eric Liu; Kevan Herold; Robert J Winchester; Mark A Hardy; Paul E Harris
Journal:  Endocrinology       Date:  2004-07-01       Impact factor: 4.736

3.  Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis.

Authors:  Martin Anlauf; Martin K-H Schäfer; Thorsten Schwark; Nicole von Wurmb-Schwark; Viktoria Brand; Bence Sipos; Hans-Peter Horny; Reza Parwaresch; Wolfgang Hartschuh; Lee E Eiden; Günter Klöppel; Eberhard Weihe
Journal:  J Histochem Cytochem       Date:  2005-08-22       Impact factor: 2.479

Review 4.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

5.  Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.

Authors:  Mei-Ping Kung; Catherine Hou; Rajesh Goswami; Datta E Ponde; Michael R Kilbourn; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-04       Impact factor: 2.408

6.  Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors.

Authors:  Martin Anlauf; Rolf Eissele; Martin K-H Schäfer; Lee E Eiden; Rudolf Arnold; Ursula Pauser; Günter Klöppel; Eberhard Weihe
Journal:  J Histochem Cytochem       Date:  2003-08       Impact factor: 2.479

7.  Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas.

Authors:  Yoshifumi Saisho; Paul E Harris; Alexandra E Butler; Ryan Galasso; Tatyana Gurlo; Robert A Rizza; Peter C Butler
Journal:  J Mol Histol       Date:  2008-09-13       Impact factor: 2.611

8.  Cellular composition of the human diabetic pancreas.

Authors:  J Rahier; R M Goebbels; J C Henquin
Journal:  Diabetologia       Date:  1983-05       Impact factor: 10.122

9.  In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET.

Authors:  Marc D Normandin; Kitt F Petersen; Yu-Shin Ding; Shu-Fei Lin; Sarita Naik; Krista Fowles; Daniel M Skovronsky; Kevan C Herold; Timothy J McCarthy; Roberto A Calle; Richard E Carson; Judith L Treadway; Gary W Cline
Journal:  J Nucl Med       Date:  2012-05-09       Impact factor: 10.057

10.  Regional differences in islet distribution in the human pancreas--preferential beta-cell loss in the head region in patients with type 2 diabetes.

Authors:  Xiaojun Wang; Ryosuke Misawa; Mark C Zielinski; Peter Cowen; Junghyo Jo; Vipul Periwal; Camillo Ricordi; Aisha Khan; Joel Szust; Junhui Shen; J Michael Millis; Piotr Witkowski; Manami Hara
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

View more
  7 in total

Review 1.  Molecular imaging of β-cells: diabetes and beyond.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quan-Yong Luo; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

Review 2.  Futility of attempts to detect and quantify beta cells by PET imaging in the pancreas: why it is time to abandon the approach.

Authors:  Abass Alavi; Thomas J Werner
Journal:  Diabetologia       Date:  2018-06-29       Impact factor: 10.122

3.  Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 Diabetes.

Authors:  Mika Naganawa; Keunpoong Lim; Nabeel B Nabulsi; Shu-Fei Lin; David Labaree; Jim Ropchan; Kevan C Herold; Yiyun Huang; Paul Harris; Masanori Ichise; Gary W Cline; Richard E Carson
Journal:  Mol Imaging Biol       Date:  2018-10       Impact factor: 3.488

4.  Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging.

Authors:  Gary W Cline; Mika Naganawa; Laigao Chen; Kristin Chidsey; Santos Carvajal-Gonzalez; Sylvester Pawlak; Michelle Rossulek; Yanwei Zhang; Jason Bini; Timothy J McCarthy; Richard E Carson; Roberto A Calle
Journal:  Diabetologia       Date:  2018-05-02       Impact factor: 10.122

5.  Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNO.

Authors:  Jason Bini; Mika Naganawa; Nabeel Nabulsi; Yiyun Huang; Jim Ropchan; Keunpoong Lim; Soheila Najafzadeh; Kevan C Herold; Gary W Cline; Richard E Carson
Journal:  J Nucl Med       Date:  2018-01-25       Impact factor: 10.057

6.  PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes.

Authors:  Jason Bini; Elizabeth Sanchez-Rangel; Jean-Dominique Gallezot; Mika Naganawa; Nabeel Nabulsi; Keunpoong Lim; Soheila Najafzadeh; Anupama Shirali; Jim Ropchan; David Matuskey; Yiyun Huang; Kevan C Herold; Paul E Harris; Robert S Sherwin; Richard E Carson; Gary W Cline
Journal:  J Nucl Med       Date:  2019-10-10       Impact factor: 11.082

7.  Clinical and scientific value in the pursuit of quantification of beta cells in the pancreas by PET imaging.

Authors:  Gary W Cline; Timothy J McCarthy; Richard E Carson; Roberto A Calle
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.460

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.